1 / 28

SI’s Mysterious Cellulitis

SI’s Mysterious Cellulitis. Sandra Katalinic – Pharmacy resident July 13, 2009 Pharmaceutical Care rotation. Presentation Outline . Our patient Her diagnosis Cellulitis pathophysiology CC, social history, PMH etc. ROS, labs, current treatment Drug related problems Clinical question

tilly
Download Presentation

SI’s Mysterious Cellulitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. SI’s Mysterious Cellulitis Sandra Katalinic – Pharmacy resident July 13, 2009 Pharmaceutical Care rotation

  2. Presentation Outline • Our patient • Her diagnosis • Cellulitis pathophysiology • CC, social history, PMH etc. • ROS, labs, current treatment • Drug related problems • Clinical question • Literature review • Plan and outcomes

  3. Learning Objectives • Cellulitis vs necrotizing fasciitis – differences in presentation and causative agents • Cellulitis vs. necrotizing fasciitis – differences in treatment • Recommended monitoring of vancomycin serum levels

  4. Our Patient: SI • 73 y/o Caucasian female • c/c rapidly spreading cellulitis on her right leg • Erthythmatous rash to mid thigh • Large 10 x 4cm blister on back of calf • Blistering to lateral malleolus • Source: cracked callous (?) • ? cellulitis or necrotizing fasciitis

  5. Cellulitis • Dermis & epidermis  superficial fascia • Serious b/c can get into lymphatic / CV system (bacteremia in 30%) • Pathogens: • S. pyogenes, S. aureus, • 1st line (empiric) nafcillin / oxacillin, cefazolin x5-10 days • MRSA • TMP-SMX (CA-MRSA), Vancomycin (10-14 days)

  6. Necrotizing Fasciitis • Rapidly spread (hours), gas production, muscle involvement • Erythmatous, hot, swollen, shiny, ++ tender, bullae filled with clear fluid, maroon colour after several days • Fever, chills, leukocytosis • Clostridium perfringens aka “gas gangrene” • Gm + anaerobe • 1st line tx = Pen G + clindamycin x 10-14 days

  7. Past Medical History

  8. Social History • Previous smoker • 25 pk/yr hx; quit 40 yrs ago • Well balanced diet • 1.5 espresso sized cups coffee / day • Drinks occasionally • No previous flu or pneumococcal vaccine • No recreational drug use • Codeine intolerance  “violently ill”

  9. Goals of therapy • Cure disease • Cure SI’s cellulitis infection • Prevent resistance of causative microorganism • Tailor abx therapy to diagnosis / cultures when available

  10. In the Hospital… • Admitted to Emergency Dept: • Vanco 1.5g IV load • Pen G 4mu q4h • Clindamycin 900 mg q8h • Transferred to SS: • Same abx as above • MgSO4 2gm IV q8h • Gravol 25-50mg IV/PO q4h prn • Morph 5-10mg q4h prn • APAP 1-2 tabs q4h prn * HOME MEDS NOT ORDERED**

  11. In the Hospital • Logic: • Vancomycin = MRSA, Gm + • Penicillin G = Gm + • Clindamycin = anaerobes • *Clindamycin + Penicillin G = first line for gas gangrene • Aka necrotizing fasciitis • Clostridium (Gm + anaerobe)

  12. Review of Systems

  13. Review of Systems cont’d

  14. Drug Related problems

  15. The Plan • Maintain pt on 3 abx’s • Until infectious agent identified • Calculate vancomycin kinetics and adjust dose accordingly

  16. The Plan • Other recommendations • KCl 40 mEq, monitor K+ daily • Monitor reaction if morphine given • Monitor for UTI symptoms (BUF) • Start sennosides • Counsel on adequate calcium + Vit D intake (1500mg Ca, 800 IU vit D)

  17. Monitoring • Vancomycin Levels 10-15 mg/L • Kidney function : SrCr, GFR, urine output • SrCr 3x weekly while on vancomycin • SE’s: ototoxicity, neutropenia, phlebitis, • Cellulitis:  erythema / edema,  blistering, regressing margins • Ø systemic symptoms (fever, nausea, chills) •  WBC’s

  18. 8? Or 10? • Dr. Ensom Says: target 8-10mg/L for cellulitis • Northern Health says: target 10-15mg/L • What are the current recommendations?

  19. The Evidence • Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists • Michael Rybak, Ben Lomaestro, John C. Rotschafer, Robert Moellering Jr., William Craig, Marianne Billeter, Joseph R. Dalovisio, and Donald P. Levine

  20. The Evidence • Pub med search from 1958-2008 of all relevant peer reviewed studies in English • Search terms: vancomycin pharmacokinetics, pharmacodynamics, efficacy, resistance, and toxicity.

  21. The Evidence • Vancomycin MIC’s required to kill bacteria are on the rise • Vancomycin kills in a time dependant manner (i.e. exposure to levels >MIC affect killing) • Target 5-10mg/L may not achieve desired exposure in higher (but susceptible) MIC bugs • Always maintain vancomycin levels above 10 mg/L to avoid resistance.

  22. What this means to us? • Target doses for 10-15 mg/L • Higher serum vancomycin levels prevent resistance without an increase in nephrotoxicity • Vancomycin nephrotoxicity found to be due to impurities from processing / manufacturing • Today’s product very unlikely to have this impurity and occurrence of nephrotoxicity is very low

  23. What really happened… • Patient was given1500mg load • Pharmacist dosed 1000mg q12h • Level done prior to 3rd dose = 9.5 • Patient rapidly improving, margins regressing • Blood culture –’ve after 48 hrs

  24. What really happened… • Kinetics calculations done: • CrCl = 68.8 ml/min; K = 0.6h-1 • T½ = 11hours; VD = 44.1L • 4-5 t½’s required to reach SS (44-55hours) • Level prior to 3rd dose (36hrs = too early) • Expect level to increase • Maintain dose at 1g q12h

  25. What really happened • Requested pk and tr levels, for kinetic monitoring • July 9th trough = 8.5, peak = 22.7 • Kinetics calculations done w/ pk/tr levels •  dose to 1500mg q12h • Expect trough 11.3

  26. What really happened • Vanco D/C’s by internal med later that day • necrotizing fasciitis and MRSA ruled out • patient recovering quickly

  27. Update • Today: Pt progressing, mobilizing regularly • Erythema only affecting lower leg • Bullae / blistering ↓, WBC 5.5x109/L • Regular BM’s • Stable lytes (including K+) • Chest clear • No s/s of UTI (BUF) • MD considering switch to PO clindamycin

  28. References • Dipiro JT, et al. Pharmacotherapy: A pathopysiologic approach.7th ed. New York. 2008: p. 1801-10. • Hill-Blondel. Bugs and Drugs 2006. Edmonton. 2006: p.181-3. • Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98. • Vancomycin dosing and monitoring in adults. Pharmacist’s Letter/Prescriber’s Letter 2009;25(2):250215.

More Related